Karyopharm announces update to Phase 3 XPORT-EC-042 Trial
Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial ...
Business Wire6h
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...
Science Daily15h
Newfound circuit better explains how the brain recognizes what is familiar and important
A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or just 'background noise.' ...
emjreviews.com1d
New Therapy Hope for Hard-to-Treat DLBCL
Epcoritamab combined with GemOx shows deep, durable responses in transplant-ineligible relapsed/refractory diffuse large ...